The vaccine Pfizer BioNTech is 73.2% effective in preventing Covid-19 Among children aged 6 months to 4 years, new data from the companies this Tuesday (23) show that two months after the start of the vaccine’s application USA For that age group.

The Pfizer-BioNTech vaccine was approved in June for children under 5 in the US, based on data showing the vaccine produces an immune response similar to that of adults.

A preliminary analysis based on ten symptomatic Covid-19 cases in the study suggested a vaccine efficacy of 80.3%. Experts cautioned that the data is preliminary because of the small number of symptomatic cases.

Updated data released Tuesday showed that 13 children developed Covid-19 at least seven days after receiving the third dose of the Pfizer-BioNTech vaccine, compared with 21 cases among those who received the placebo.

Most cases caused Variant of omicron BA.2It was prevalent in the months of March and April when the study was conducted.

Pfizer and BioNTech said they are preparing a US approval application for a so-called bivalent vaccine targeting Omicron’s BA.4/BA.5 subvariants for children under 12 years of age.

The companies applied Monday for US approval of the bivalent vaccine as a booster in people 12 years and older.